Early Type 2 Diabetes Achieves Remission With Intensive Outpatient Pharmacotherapy: RCT
A recent randomized control trial published in the Indian Journal of Endocrinology and Metabolism in April 2025 demonstrates that early Type 2 diabetes can be actively reversed rather than merely managed, with an intensive outpatient pharmacotherapy and lifestyle protocol achieving an impressive 31.04% overall remission rate.
Due to the practical limitations and complications associated with metabolic surgery and severe weight loss programs, Walia et al. evaluated a temporary, intensive pharmacological approach to type 2 diabetes remission. The study investigated whether a 3-month pharmacotherapy regimen targeting glucolipotoxicity could successfully restore beta-cell function.
Therefore, the single-center, open-label RCT evaluated 29 insulin-naïve adults with early type 2 diabetes (duration <5 years, HbA1c <8.5%) and no major comorbidities. Patients underwent 3 months of strict glycemic control using either an intervention regimen (metformin, dapagliflozin, or liraglutide) or a control regimen (metformin, glimepiride, or vildagliptin). Following this active phase, all medications were withdrawn for 3 months to assess the primary endpoint of sustained remission (defined as an off-treatment HbA1c <6.5%), supported by mixed meal tolerance and bioelectrical impedance testing.
Key Clinical Findings of the Trial Includes:
Remission Rates: Investigators revealed that 28.57% of patients in the intensive intervention arm and 33.33% in the active control arm successfully maintained remission three months after complete medication withdrawal.
Weight Reduction: Researchers observed significant body mass reductions across both cohorts, with the intervention group losing a median of 4.9 kg compared to 3.0 kg in the control group.
Beta-Cell Recovery: Evaluators demonstrated that subjects achieving sustained remission exhibited a significantly higher post-treatment disposition index (5.25 versus 2.04), indicating substantial beta-cell functional recovery.
Insulin Sensitivity: Scientists noted that post-treatment insulin resistance was significantly diminished in the remission cohort, showing a Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) score of 2.09 versus 3.72 in those who relapsed.
Adverse Events: Clinicians found that while transient gastrointestinal symptoms were more frequent in the intervention arm (72.73% versus 15.39%), hypoglycemic events were entirely absent in this group compared to two instances in the control arm.
The results suggest that intensive, short-term pharmacotherapy coupled with lifestyle modifications can effectively alleviate glucotoxicity and facilitate a sustained remission phase in nearly one-third of treated patients. Achieving near-normal glycaemia provides a viable outpatient pathway to positively alter the disease trajectory without continuous pharmacological dependence.
Thus, the trial concludes healthcare professionals could consider early, intensive pharmacological management as a frontline strategy to potentially reverse early-stage diabetes rather than exclusively focusing on lifelong symptom control.
While the promising outcomes of the trial are constrained by a small sample size and a relatively brief follow-up period, they gracefully pave the way for larger, extended clinical studies to further validate these transformative therapeutic possibilities.
Reference
Sudhayakumar A, Arjunan D, Bhansali S, Bhujade H, Bhadada SK, Malhotra S, et al. Realisation of remission of diabetes using pharmacotherapy (DiaRem-1). Indian J Endocr Metab 2025;29:217-23.
